|
Delayed
Toronto S.E.
15:52:51 2026-10-13 EDT
|
5-day change | 1st Jan Change | ||
| 30.48 CAD | -0.72% |
|
+2.59% | +22.71% |
| 10-13 | Goldman Sachs Adjusts Price Target on Amgen to $475 From $450 | MT |
| 10-12 | Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1,040B | |||||
| 599B | |||||
| 485B | |||||
| 350B | |||||
| 345B |
- Stock Market
- Stocks
- AMGN Stock
- AMGN Stock
- Charts Amgen Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
